Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 6/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657412 | 0.87 | MAPK1 (0.62) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL3215185 | 0.85 | AURKA (0.60) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL3197568 | 0.84 | MAPK1 (0.73) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL4881338 | 0.81 | CA1 (0.56) | MAPK1MEN1NPC1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL4884494 | 0.81 | CA1 (0.55) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL27792742 | 0.79 | MAPK1 (0.56) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL4621510 | 0.77 | MAPK1 (0.61) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL3209130 | 0.76 | BRD4 (0.55) | MAPK1MEN1NPC1LMNAMAPT | |
| SCHEMBL28020002 | 0.76 | SYK (0.56) | — | |
| Hydrochloric Acid SCHEMBL27735100 | 0.75 | AURKA (0.57) | MAPK1MEN1NPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2121634-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SuperGen, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | JAK2, JAK1, IRAK4 | MAPK1 78/4885MEN1 4854/4885NPC1 3993/4885 |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | MAPK1 385/4885MEN1 3865/4885NPC1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.